These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN Carneiro A; Meireles A; Castro Sousa JP; Teixeira C Ther Adv Ophthalmol; 2020; 12():2515841420917768. PubMed ID: 32548568 [TBL] [Abstract][Full Text] [Related]
6. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. Currie CJ; Holden SE; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):33-43. PubMed ID: 28881150 [TBL] [Abstract][Full Text] [Related]
7. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN Panos GD; Arruti N; Patra S Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704 [TBL] [Abstract][Full Text] [Related]
10. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Ding X; Li J; Hu X; Yu S; Pan J; Tang S Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319 [TBL] [Abstract][Full Text] [Related]
11. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema. Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913 [TBL] [Abstract][Full Text] [Related]